IBIMA

Publishing

mobile

JMED Research

Research Article

Inhibition of Nitric Oxide Generation in Mononuclear Splenocytes from Multiple-Low-Dose-Streptozotocin Diabetic Mice

Authors

Liliana Karabatas and Claudia Pastorale

Centro de Investigaciones Endocrinológicas "Dr. César Bergadá" (CEDIE), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) – División de Endocrinología, Hospital de Niños "Ricardo Gutiérrez", Ciudad Autónoma de Buenos Aires, Argentina

Abstract

Mice injected with multiple low dose of streptozotocin (mld-SZ) or transferred with mononuclear splenocytes (MS) from mld-SZ donors constitute animal models that allow the study of autoimmune diabetes. Mld-SZ mice show a progressive beta-cell destruction iniciated during non-specific islet inflammation involving free radicals as nitric oxide (NO°). Pharmacological inhibitors of NO° synthase delay or prevent the outbreak of disease, but have deleterious side effects when administered *in vivo*. The aim of this study, was to clarify the role of NO° on the ability of MS from mld-SZ mice to impair insulin secretion. Also, we investigated the beneficial effects of using NO° synthase inhibitors *in vitro* on anti-beta cells agression. **Methods:** NO° was measured in cultured MS and islets of Langerhans isolated from

mice at days 4 to 16 after the first mld-SZ injection. MS were also cultured with an inhibitor of NO° production, L-N^G-monomethyl-arginine (L-NMMA), and then: a) injected in syngeneic mice to evaluate their insulin secretion patterns or b) co-cultured with islet cells to estimate the capacity of MS to exert *in vitro* cellular immune aggression. **Results:** Cultured islets of Langerhans and MS from mld-SZ mice showed increases in NO° production ($p > 0.05$). MS from mld-SZ mice, obtained at days 4 to 9 and precultured with L-NMMA showed ameliorations in their deleterious effect on insulin secretion from transferred recipient mice and from co-cultured islet cells ($p < 0.05$). **Conclusions:** These results suggest that the inhibition of NO° production *"in vitro"* reduced the aggressive capacity of MS from mld-SZ mice avoiding, at least in part, beta cell damage and destruction.

Introduction

Type 1 diabetes is a disease characterized by the specific destruction of insulin producing pancreatic beta-cells by the immune system (Cernea et al., 2008; Lehuen et al., 2010; Buschard, 2011; Eizirik et al., 2009; Padgett et al., 2013). Several animal models have been developed to study the islet physiopathology leading to autoimmune diabetes mellitus. One of these models is the multiple low dose of streptozotocin (mld-SZ) treated mouse that presents cellular and humoral immune reactions against beta cells, presumably, made antigenic by mld-SZ injections (Like et al., 1976; Per-Ola et al., 2000; Mabley et al.,

2008) and shows a time course of histologic changes and progressive impairments in insulin secretion and lipid metabolism. The process includes an increment in apoptotic islet cells, followed by insulitis and microfocal islet cell death. Also, an increase of plasma free fatty acids is accompanied by a diminished activity of pyruvate dehydrogenase complex in skeletal muscle, suggesting a reduced glucose oxidation. These changes precede appearance of hyperglycemia and impaired insulin secretion (O´Brien et al., 1996; Pighin et al., 2005 and Karabatas et al., 2005).

Another animal model consists of an adoptive transfer of mononuclear splenocytes (MS) from mld-SZ diabetic donors (diab.MS) to healthy syngeneic recipients. In these mice, a diminished insulin secretion is present 15 days after the transfer

procedure, and a preferential trapping of transferred diab.MS in islets of recipient mice was observed. Diab.MS obtained as early as day 4, were able to impair insulin secretion in transferred normal syngeneic recipients (Buschard et al., 1977; Pastorale et al., 2002; Karabatas et al., 2000 and 2005).

It has been reported that in mld-SZ treated mice, beta-cell destruction can be initiated during non-specific islet inflammation involving toxic mediators such as cytokines and highly reactive free radicals as oxygen species and nitric oxide (NO°), produced by macrophages and endothelial cells. The beta-cells are particularly weakly protected against the toxicity of free radicals having a great vulnerability and sensitivity to this reactive species. Also the endocrine beta-cells become an important source of NO° production when NO° synthase is

induced by IL-1 (Karabatas et al., 1996; Flodstrom et al., 1999; Rydgren et al., 2002; Mabley et al., 2004; Lenzen, 2008; Eizirik et al., 2009; Yasuda et al., 2009). By using pharmacological inhibitors of NO° synthase, it has been evidenced that several of the deleterious actions of cytokines on rodent islet function "in vitro" are mediated by NO° formation. Several reports have indicated that inhibition of free radicals production protect against mld-SZ-induced diabetes in mice, since in vivo studies have shown a delay or prevention of the outbreak of disease after treatment with NO° synthase blockers (Karabatas et al., 1996; Maksimovic-Ivanic et al., 2002; Rydgren et al., 2002; Yang et al., 2003; Mabley et al., 2004 and 2008;). However, the lack of specificity of NO° synthase pharmacological inhibitors, which to a varying degree block inducible and constitutive isoform of the

enzyme, leads to uncontrolled side effects (blood pressure, neurotransmission, body weight) when administered *in vivo*.

The aim of this study was to investigate the role of NO° on the ability of diab.MS to impair insulin secretion when injected in normal recipient mice or when co-cultured with dispersed islet cells. We studied nitric oxide production in cultured MS and islets of Langerhans, isolated from control or mld-SZ mice at 4, 6, 9, 12 and 16 days after the first injection. MS were also cultured with an inhibitor of nitric oxide production, L-N^G-monomethyl-arginine (L-NMMA). After being properly washed, these cells were used to study:
a) insulin secretion patterns in mice transferred with MS and
b) the capacity of diab.MS to exert an *in vitro* anti beta-cell immune aggression when co-cultured with dispersed islet cells.

Materials and Methods

Animals

Male C57BL/6J inbred mice weighing 21 to 25 g were obtained from the Centro Nacional de Genetica Medica, Buenos Aires, Argentina. Three-month-old male Wistar rats were also used as source of islet cells for co-culture experiments. Animals were housed in rooms with controlled temperature (23°C) and a fixed 12-hour artificial light-dark cycle and had free access to water and to a standard laboratory chow (Carhill, Buenos Aires, Argentina). The protocols of animal use comply the guidelines recommended by the National Institutes of Health; and were approved by the Institutional Review Board at Hospital de Niños R. Gutiérrez (#CODI-1811).

Mice Injected with Multiple Low-Dose Streptozotocin (mld-SZ)

C57BL/6J mice were injected intraperitoneally with 0.1 ml citrate buffer (0.1 mol/l trisodium citrate, 0.1 mol/l citric acid, pH=4.5), or with 40 mg/kg body weight of streptozotocin (SIGMA,USA) dissolved in 0.1 ml citrate buffer, for five consecutive days. Animals were killed by cervical dislocation at days 4 (before the fourth injection), 6, 9, 12 or 16 after the first injection of SZ or buffer alone. Blood samples for determination of plasma glucose levels were obtained by retroorbital sinus puncture in unanesthetized, nonfasted mice 24 h before the beginning of mld-SZ or buffer injections and on day 4, 6, 9, 12 and 16 after the first injection. Pancreata and spleens were obtained from mice at the time of death.

Islets of Langerhans were obtained from collagenase-treated (SIGMA, USA) mice pancreas according to the method of Lacy and Kostianovsky (1967), and were perifused to evaluate glucose-induced insulin secretion, or cultured 22 h to evaluate NO° production as described below.

Mononuclear splenocytes (MS) were aseptically isolated by shredding the spleens with steel wire mesh with sterile NaCl 154 mmol/l solution (Buschard et al., 1977; Karabatas et al., 2000 and 2005). MS were obtained using a Lymphoprep™ gradient (Nycomed Pharma, Norway) and then washed three times with sterile saline solution. Cell viability was assayed by the Trypan blue exclusion test (Phillips, 1973) and was 95 to 98%. Isolated MS were used to evaluate NO° production in 22 h cultures (see Nitrite production). MS were also cultured 22 hs without or with

0.5 mM L-N^G-monomethyl-arginine (L-NMMA, an inhibitor of nitric oxide synthase) and then transferred into syngeneic recipient mice or used to study "in vitro" cellular immune aggression (CIA).

Nitrite Production in Cultured Islets and MS

Islets of Langerhans and MS were obtained as described above from mice killed 4, 6, 9, 12 or 16 days after the first injection of mld-SZ or citrate buffer alone. Groups of 200 islets were cultured for 22 h under an atmosphere of 95% air/5% CO_2 in 400 μl of RPMI 1640 (without phenol red) supplemented with 60 mg/l streptomycin, 1 mmol/l sodium pyruvate, 10 ml/l non-essential amino acids 100X, 23.8 mmol/l NaHCO$_3$, 10 mmol/l HEPES and 10% heat inactivated

fetal calf serum (Gibco, UK). Also, 10^7 MS were cultured 22 h in culture medium.

Nitrite determination was performed with 250 μl of supernatants of cultured islets or MS mixed with 250 μl of Griess reagent and incubated for 10 minutes at room temperature. Nitrite was determined according to the method described by Green (1982). For our experiment, the detection limit was 0.5 μM, corresponding to 0.8 pmol/islet and 20 pmol/10^6 MS. Intra- and interassay coefficients of variation on the standard curve were 1 μM: 5.5%, 9,4%; 5 μM: 1.2%, 11.0%; 25 μM: 0.3%, 4.0%. Results are expressed as pmol of nitrite per islet or pmol of nitrite per 10^6 MS.

In another set of experiments, MS were cultured 22 h with or without L-NMMA 0.5 mM and nitrite was determined in

supernatants. Nitrite levels of medium without MS (with or without L-NMMA) were subtracted if their values were above the detection limit.

Transfer of MS from Mld-SZ Mice to Syngeneic Animals

MS obtained from mld-SZ-mice (diab.MS) or from citrate buffer-injected mice (ctr.MS) at days 4, 6, 9, 12 or 16 after the first injection were washed twice with RPMI 1640 and cultured in this medium (5×10^7 MS/50 ml of culture medium) for 22 hs with or without 0,5 mM L-NMMA. Afterward MS were washed twice with sterile saline solution. Viability of MS was then assesed by Trypan blue exclusion (Phillips, 1973) and 5×10^7 viable MS (90-95% viability), suspended in 0.2 ml sterile NaCl 154 mmol/l solution) were injected ip in C57BL/6J male recipient mice of 22-24 g. Fifteen

days after the transfer procedure, recipient mice were killed by cervical dislocation and their pancreas were quickly removed and processed for isolated islet perifusion as described below. Blood samples from unanesthetized, non-fasted recipient mice were obtained by retroorbital sinus puncture before and 15 days after being transferred. All experiments were carried out between 10:00 and 12:00 AM.

Perifusion of Pancreatic Islets

Islets of Langerhans from mld-SZ mice or from mice transferred with MS were perifused (25-40 islets per chamber) as described previously (Karabatas et al., 2000 and 2005). Krebs-Ringer-bicarbonate buffer was utilized as the perifusion buffer, and was supplemented with 1% (w/v) dextran 70 (Sigma, St. Louis,

Missouri, USA) and 3.3 mmol/l glucose. The pH of the buffer, kept under constant 95% O_2, 5% CO_2 gassing was 7.38-7.40. Samples were collected, after an initial 15 min recuperation period, on 0.2 ml of 0.25 mol/l EDTA in tubes kept at 4°C and immediately frozen at -20°C. Samples from min 1 and 2 were used for baseline determinations. A stimulus of 16.5 mmol/l glucose was added to the perifusion buffer from min 3 to 40. Islets were perifused with buffer containing 3.3 mmol/l glucose from min 40 to 50. Perifusion flux was 0.8-1.1 ml/min.

"In Vitro" Cellular Immune Aggression (CIA)

The cellular immune aggression was evaluated measuring insulin secretion from dispersed rat islet cells co-cultured with MS. Diab.MS and ctr. MS were obtained at days 4, 6, 9, 12 and 16 after the first

injection and were cultured 22 hs in RPMI 1640 with or without L-NMMA 0,5 mM and washed twice with sterile saline solution. Viable MS (90-95% viability) were used to determine CIA.

Isolation of Dispersed Rat Islet Cells

To obtain islet cells suspensions, freshly isolated rat islets (from collagenase treatment) were subjected to EDTA and trypsin (Sigma, St. Louis, Mo., USA) (Ono, 1977). The cells were suspended in basal Minimal Essential Medium with Eagle salts supplemented with 10% (v/v) fetal calf serum, 2 mmol/l glutamine, 1 mmol/l sodium piruvate, 0.814 mg/l non-essential amino acids (Gibco, UK), 100 U/ml penicillin and 100 µg/ml streptomycin. Cell viability was estimated by the Trypan blue exclusion test (Phillips, 1973) and

only cell suspensions having at least 90% viable cells were employed.

Islet Cell Stimulation

The islet cell suspension was placed in 96-well Falcon microtest plates (Becton Dickinson, USA) at 5×10^3 cells/100 µl per well, with addition of 4×10^5 MS from either control or diabetic mice (in 100 µl), or basal medium (100 µl) and incubated for 18 h. Ten wells were used for each determination. At the end of this period, wells were carefully washed and the supernatant collected to asses prestimulatory insulin release. The medium was replaced by 200 µl basal medium (glucose 5.5 mmol/l) or 200 µl stimulatory medium (glucose 16.5 mmol/l plus theophylline 5.5 mmol/l). Five wells were used for each basal or stimulatory medium. MS remained with

cells during both basal and stimulatory periods. Supernatants were withdrawn after 5 min and rapidly frozen for insulin determinations. Islet cells function was expressed as the insulin secretion (μU/5000 cells) during 5-min incubation period in the presence of basal or stimulatory medium (Boitard et al., 1982; Karabatas et al., 1996 and 2000). Results of cellular immune aggression test were reproducible with a 3.89% inter-assay and 4.20% intra-assay coefficient of variation (CV), both for ctr.MS or diab.MS.

Analytical Methods

Serum glucose levels from non fasted mice were determined using Glicemia Enzimatica Kit (Wiener Lab, Buenos Aires, Argentina).

Insulin was determined in samples from perifusion and in supernatants from islet cells-MS cultures by the method of Herbert et al. [33]. Pork monoiodine ^{125}I-insulin was obtained from CENEXA, Facultad de Medicina, Universidad Nacional de La Plata, Argentina. Rat standard insulin was obtained from Novo Research Laboratories (Denmark). Guinea pig anti-porcine insulin antiserum was sufficiently "non-specific" as to allow pork labeled insulin to be displaced by mouse and rat insulin. Insulin assay sensitivity was 0.5 µU/ml; intra-assay CV was 8.7%, 6.2% and 5.1% for 1-5, 5-10 and 10-50 µU insulin/ml determination ranges respectively; inter-assay CV were 6.6%, 5.0% and 5.2% for the given ranges.

Statistical Analysis

Results were expressed as mean ± SEM. Statistical significance was determined by ANOVA for plasma glucose levels, insulin secretion and nitrite concentration. When significance was found, Scheffe's post hoc comparisons were made; p less than 0.05 was accepted as statistically significant.
To evaluate insulin secretion from perifused pancreatic islets we integrated the areas under stimulated-insulin secretion curves: first secretory peak was integrated between min 3 to 7; and the second peak between min 9 to 40 of perifusion.

The experimental design and different procedures were schematized in Figure 1

Please see figure 1 in the PDF version

Results

Mice injected with mld-SZ show a significant and progressive increase in serum glucose levels from day 9 to day 16 after the first injection of the diabetogenic drug (Table 1).

Please see Table 1 in PDF version

Basal insulin secretion levels from perifused pancreatic islets are not significantly different between control and mld-SZ mice at all intervals (controls: 0.23 ± 0.02, 16 days after mld-SZ: 0.24 ± 0.01 μU/min/islet; n=4, p: N.S.).

Figure 2 shows the waveforms of glucose-stimulated insulin secretion from perifused islets (upper panel) and the areas under first and second phases of glucose-induced insulin secretion (lower panel). Control mice present a biphasic pattern with a first phase lasting from minute 3 to minute 7, and the second phase lasting from minute 10 to 40. Afterwards, when perifusion buffer contains 3.3mM glucose, insulin secretion returns to basal levels (min 50). Mld-SZ mice present normal secretory patterns at days 4 and 6 and significant reductions in the first phase of glucose-stimulated insulin secretion at days 9, 12 and 16 compared with control mice. Values obtained at days 12 and 16 are lower than those from day 9. The second phase of glucose-stimulated insulin secretion is significantly decreased in mld-SZ mice at days 12 and 16.

Please see Figure 2 in PDF version

Cultured islets of Langerhans, isolated from mld-SZ mice, show a significant increase in nitric oxide production, at all time intervals, when compared with control mice. The highest value is obtained when islets are isolated at day 6 after the first injection of the diabetogenic drug (Figure 3, upper panel). In agreement with these findings, cultured diab.MS also show increments in nitric oxide production, reaching the maximum level at day 6 (Figure 3, lower panel). In another set of experiments ctr.MS and diab.MS were isolated at 6 or 16 days after the first injection and cultured 22 hours with or without 0.5 mM L-NMMA to evaluate nitric oxide production in supernatants. Results show that L-NMMA decreases the production of nitric oxide in diab.MS to control values while it has no effect on ctr. MS (Figure 4).

Please see Figure 3 and Figure 4 in PDF version

Diab.MS impair beta cell function when transferred to normal syngeneic mice, since perifused freshly isolated islets from recipient animals show a significant reduction in first-phase of glucose-stimulated insulin secretion. However, when diab.MS were precultured with L-NMMA before being transferred, we observe changes in this deleterious effect since first phases of insulin secretion are:
a) normal in mice transferred with L- NMMA-treated diab.MS obtained at days 4 and b) partially impaired when these MS are isolated at days 6 and 9.

On the other hand, preculture with L-NMMA has no effect when diab.MS were obtained at days 12 or 16, since insulin secretion

show similar reductions (comparing to recipients of diab.MS without L-NMMA). (Table 2).

Please see Table 2 in PDF version

Each perifusion corresponded to islets isolated from a a single transferred mouse.

In order to investigate the *in vitro* cellular immune aggression we co-cultured dispersed rat islet cells with ctr.MS or diab.MS, and measured insulin secretion in the culture medium. No significant differences were found in the pre-stimulatory period or in basal condition (data not shown). Under stimulatory condition, insulin is significantly reduced when islet cells are co-cultured with diab.MS (obtained at all time intervals). However when diab.MS,

obtained at days 4 to 12, were precultured with L-NMMA, they exert a lower functional immune aggression against islet cells, since insulin levels in the culture medium are significantly higher. At later stages (day 16) L-NMMA had no preventive effect on diab.MS since they are capable to impair insulin secretion to similar levels than diab.MS without LNMMA (Table 3).

Please see Table 3 in PDF version

Discussion

A variety of cellular components are involved in the development of type 1 diabetes: both CD4+ and CD8+ T cells, monocytes, macrophages and NK cells. Also, proinflammatory cytokines play

essential roles in the pathogenesis of the disease (Lehuen et al., 2010; Padgett et al., 2013) .

Mice injected with mld-SZ develop autoimmune diabetes with the appearance of progressive hyperglycemia. Mld-SZ affects beta cells eliciting a non-specific islet inflammation involving toxic mediators as free radicals and cytokines followed by immune destruction and insulitis. In this model, a variety of procedures demonstrated the role of immune cells in beta cell damage. Herold et al., (1987) showed that administration of anti-L3T4 or anti-Lyt-2 monoclonal antibodies to mld-SZ mice promoted a reduction in hyperglycemia and in splenic T-lymphocytes subsets, and a prevention of insulitis. Also, athymic mice did not develop insulitis or hyperglycemia after adminitration of mld-SZ, but when immunity was restored by thymus grafting insulitis and

hyperglycemia became evident. This highlight the role of T cells in the development of the disease (Paik et al., 1980; Nakamura et al., 1984). In addition, it has been proposed that the balance between subsets of T cells (pro or anti inflammatory) is important to prevent type 1 diabetes. Yaochite et al., (2013) demonstrated that mice lacking IL-17 receptor showed an impairment in mld-SZ diabetic course with reduced insulitis and beta cell preservation.

Earlier events that preceded the onset of hyperglycemia had been described in mld-SZ mice: a decrease of GLUT2 protein and mRNA expression in pancreatic islets, increases in the percentage of islet apoptotic cells and incipient insulitis at day 6 after the first streptozotocin injection. The free radical nitric oxide (NO°), generated by inducible nitric oxide synthase (iNOS) has been

implicated in beta cell destruction leading to type 1 diabetes since iNOS is mostly not expressed under normal conditions but can be induced by cytokines to produce large amounts of NO°, that often function as a cytotoxic molecule for beta cells (O´Brien et al., 1996; Wang et al., 1998; Rydgren et al., 2002; Karabatas et al., 2005; Mabley et al., 2004 and 2008; Lenzen, 2008; Cernea et al., 2008; Eizirik et al., 2009; Yasuda et al., 2009; Lehuen et al., 2010). In agreement with these previous findings (2005), we show here that hyperglycemia is present in mld-SZ-treated mice from day 9 after the first injection. Moreover, perifused pancreatic islets show a progressive reduction in the first phase of glucose-induced insulin secretion while the second secretory peak significantly diminishes from day 12.

We have also found that increments in NO° production, both in cultured islets and MS from mld-SZ, appear as early as day 4 after the first injection of the diabetogenic drug, reaching its highest level at day 6. This increased iNOS activity may constitute an important factor in the cascade of events leading to beta cells dysfunction and culminating in mld-SZ-induced diabetes. Flodstrom et al., (1999) and Per-Ola et al., (2000) reported that iNOS knockout mice treated with mld-SZ show: no changes in islet blood flow, a markely decrease in insulitis and a reduced sensitivity to develop overt diabetes. These findings have raised interest in the question of whether inhibitors of iNOS could be used to prevent the development of Type 1 diabetes.

A variety of procedures and therapies that delete, suppress, or modulate functions of the immune and inflammatory system can block the response against islet beta cells (Stosic-Grijicic et al., 2001; Rydgren et al., 2002; Yang et al., 2003; Mabley et al., 2004 and 2008 and Karatug et al., 2013). In a previous work we showed that mld-SZ mice injected ip with L-NMMA had normoglycemia, preserved first and second glucose-induced insulin secretion and a diminished anti-beta cell immune aggression (Karabatas et al., 1996). It has been reported that the use of an iNOS inhibitor plus an oxygen species scavenger leads to decreases in hyperglycemia and incidence of diabetes, a higher pancreatic insulin content and absence of pancreatic oxidative stress (Mabley et al., 2004). Also, mld-SZ mice treated with micophenolato mofetil reduced local production of IFN-gamma as well as IL-12 and NO° production by spleen and peritoneal cells

in mld-SZ mice (Maksimovic-Ivanic et al., 2002). Moreover, Stocic-Grijicic et al., (2001) and Mabley et al., (2008) showed, in "in vivo" studies, a delay or prevention of the outbreak of disease after treatment with NOS blockers. These findings raised the question of whether inhibitors of iNOS could be used *in vivo* to prevent the development of type 1 diabetes. However, a high selectivity for iNOS seems important to prevent side effects that might arise from inhibiting the other isoforms. Also, a drug with a high selectivity for iNOS can inhibit enzyme molecules from cells not implicated in beta cell damage.

Diabetes transfer from mouse to mouse constitutes an experimental model in which insulin secretion impairment was induced in healthy naïve recipient mice by MS from mld-SZ diabetic donors and it appears to be a useful system to study

mechanisms involved in the onset and modulation of autoimmune pancreatic aggression (Enghofer et al., 1998; Karabatas et al., 2000 and 2005 and Pastorale et al., 2002).

Paik et al., (1980) showed that splenocytes from mld-SZ +/nu mice induced transient glucose intolerance in nu/nu recipients and this effect was eliminated when splenocytes were depleted of T cells. In addition, Arata et al., (1994) showed that diab.MS induced abnormal glucose tolerance and impaired insulin secretion in healthy syngeneic recipients; when diab.MS were labeled with $Na_2{}^{51}CrO_4$, they showed a specific homing towards the pancreas of recipient mice indicating an early event in the immune aggression. Also, peripheral blood mononuclear cells from newly diagnosed type 1 diabetic patients migrate to the pancreas of athymic mice showing again a specific trapping

(Arata et al., 1995). Moreover, Enghofer et al., (1998) showed that transfer of lymphocytes from spleens of mld-SZ mice, stained with acridine red, resulted in increased lymphocyte rolling and endothelial adhesion only in islets of recipient mice pretreated with a single subdiabetogenic dose of streptozotocin. It has been suggested that the pool of transferred splenic lymphocytes from mld-SZ mice contain immunologically-activated islet-specific cells that trigger the immune aggression in this diabetic model.

Here and in previous studies (2005) we show that diab.MS obtained at day 4 were able to impair glucose-induced insulin secretion when transferred to syngeneic animals. In addition we have reported (2000) that mice transferred three times with diab.MS showed hyperglycemia and diminished first peaks of glucose and arginine-induced insulin secretion. These findings

indicate that the capacity of diab.MS to impair beta-cell function can be modulated.

When diab.MS, obtained at days 6 and 16, were pre-cultured with 0.5 mM L-NMMA, NO° production diminish to control values. Is not clear why L-NMMA is unable to suppress NO° production from ctr.MS. We can speculate that the concentration of L-NMMA used in the culture was not high enough to completely inhibit NO° synthesis.

When we pre-cultured diab.MS with L-NMMA and then transferred them to syngeneic mice, we found different patterns of response: when MS were obtained at day 4 they lost the capacity to impair glucose-induced insulin secretion in recipient mice; when diab.MS were obtained at days 6 and 9 this

impairment was partial and, at day 16 completely manifested. We have not tested if L-NMMA-treated diab.MS lose the inhibition in NO° production if cultured again without L-NMMA. However, we think that the inhibition persist since mice transferred with diab.MS (pre-cultured with L-NMMA) and killed 15 days later showed a reduced impairment in insulin secretion.

The capacity of diab.MS to reduce stimulated insulin secretion can also be studied by means of co-culturing them with dispersed rat or mouse islet cells (in vitro model) as an evaluation of the cellular immune aggression (CIA). One of the features of the CIA test is the absence of conventional major histocompatibility complex restriction, since previous studies have shown that peripheral blood mononuclear cells from newly diagnosed type 1 diabetic patients were able to induce CIA in rat

and murine pancreatic beta cells. Also, MS from mld-SZ mice were found to produce CIA on dispersed rat islet cells (Boitard et al., 1982; Arata et al., 1995; Karabatas et al., 1996). In this study, we used rat islets because they are more easily isolated and hand-picked than mouse islets.

CIA seems to be specific for pancreatic beta cells, because no cytotoxicity is observed against fibroblasts, and secretion of glucagon and somatostatin remains unaffected (Boitard et al., 1982; Arata et al., 1994). In this study, diab.MS present CIA at an early stage (such as day 4 after mld-SZ) concomitantly with their increment in NO° production. These facts occur before hyperglycemia and reduced insulin secretion appear in donor mice.

Diab.MS pre-cultured with L-NMMA also exerted a reduced CIA since dispersed islet cells secreted higher levels of insulin secretion. However, the preventive effect of L-NMMA on CIA is not observed at day 16. It is possible that at later stages diab. MS affect beta cells by means of other inflammatory agents in addition to free radicals (Cernea et al., 2008; Lehuen et al., 2010; Buschard K, 2011).

Conclusions

The *in vitro* inhibition of NO° production causes a reduction in the capacity of diab.MS to impair insulin secretion in beta cells. This effect occurs both when MS are co-cultured with dispersed islet cells (CIA) or transferred to syngeneic recipient mice.

However, L-NMMA is not effective when MS are isolated from donor mice at later stages of the development of diabetes. These results suggest that modification of the aggressive capacity of diab.MS, avoid, at least in part, beta cell damage and destruction.

Acknowledgements

Declaration of Interest

References

1. Arata, M, Fabiano de Bruno, L, Goncalvez Volpini, W. M, Quintans, J. C, DÁlessandro, V. G, Braun, M and Basabe, J.C. (1994) "Beta cell function in mice injected with mononuclear splenocytes from multiple-dose streptozotocin diabetic mice." *Proceedings of the Society for Experimental Biology and Medicine*, 206(1): 76-82.

2. Arata, M, Fabiano de Bruno, L, Goncalvez Volpini, W, Gagliardi, G, Quintans, J. C and Basabe, J.C. (1995) "Insulin secretion by pancreas of athymic mice injected with peripheral mononuclear cells from insulin-dependent diabetic patients". *Metabolism* 44(11):1435-1441.

3. Boitard, C, Chatenoud, L and Debray-Sach N.(1982) " In vitro inhibition of pancreatic beta cell function by lymphocytes from diabetics with associated autoimmune diseases: a T cell phenomenon." *Journal of Immunol*, 129(6):2529-2531.

4. Buschard, K and Rygaard, J. (1977) "Passive transfer of streptozotocin induced diabetes mellitus with spleen cells." *Acta Pathologica et Microbiologica Scandinavica*, 85C(6): 469-472.

5. Buschard, K.. (2011) "What causes type 1 diabetes? Lessons from animal models." *Acta Pathologica, Microbiologica et Immunologica Scandinavica*, 119 (Suppl 132): 1-19.

6. Cernea, S and Pozzilli, P. (2008) "New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes." *Diabetic Medicine*, 25(11): 1259- 1267.

7. Eizirik, D. L, Colli, M. L and Ortis, F. (2009). "The role of inflammation in insulitis and beta-cell loss in type 1 diabetes." *Nature Reviews Endocrinology*, 5(4): 219-226.

8. Enghofer, M, Bojunga, J, Ludwig, R, Oldenburg,A,Bernd, A,Usadel, K.H and Kusterer K. (1998) "Lymphocyte transfer in streptozotocin-induced diabetes: adhesion of donor cells to islet endothelium." *American Journal of Physiology*, 274(5 Pt 1):E928-E935.

9. Flodstrom, M, Tyrberg, B, Eizirik, D. L and Sandler S. (1999) "Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes." *Diabetes*, 48(4): 706-713.

10. Green, L. C, Wagner, D. A, Glogowsky, J, Skipper, P. L, Wishnok J. S and Tannenbaum S. R. (1982) "Analysis of nitrate, nitrite, and [^{15}N]nitrate in biological fluids." *Analytical Biochemistry*, 126(1): 131- 138.

11. Herbert, V, Lau, K, Gottlieb, C. H and Bleicher, S. J. "Coated charcoal immunoassay of insulin." *Journal of Clinical Endocrinology and Metabolism*, 1965; 25: 1375- 1384.

12. Herold, K. C, Montag, A. G and Fitch, F. W. (1987). "Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozotocin." *Diabetes*, 36(7), 796-801.

13. Karabatas, L, Pastorale, C, de Bruno L. F, Maschi, F, Pivetta, O. H, Lombardo, Y. B, Chemes, H and Basabe, J. C. (2005) "Early manifestations in multiple-low-dose streptozotocin-induced diabetes in mice." *Pancreas*, 30(4): 318-324.

14. Karabatas, L. M, De Bruno, L. F, Pastorale, C, Lombardo, Y. B and Basabe, J. C. (2000) "Branched-chain amino acids enriched diet: effects on insulin secretion and on cellular immune aggression." *Proceedings of the Society for Experimental Biology and Medicine,* 224(3): 159-165.

15. Karabatas, L. M, Fabiano de Bruno, L, Pastorale, C. F, Cullen, C and Basabe, J. C. (1996) "Inhibition of nitric oxide generation: normalization of in vitro insulin secretion in mice with multiple low-dose streptozotocin and in mice injected with mononuclear splenocytes from diabetic syngeneic donors." *Metabolism*, 45(8): 940-946.

16. Karatug, A and Bolkent, S. (2013) "The potential role of combined antioxidant treatment on pancreas of STZ-diabetic mice" *Experimental and Toxicologic Pathology*, 65(3): 255-262.

17. Lacy, P. E and Kostianovsky, M. (1967) Method for the isolation of intact islets of Langerhans from the rat pancreas." *Diabetes*, 16(1):35-39.

18. Lehuen, A, Diana, J, Zaccone, P and Cooke, A. (2010). "Immune crosstalk in type 1 diabetes." *Nature Reviews Immunology*, 10(7): 501-513.

19. Lenzen, S. (2008) "Oxidative stress: the vulnerable ß-cell." *Biochemical Society Transactions*, 36(Pt3): 343-347.

20. Like, A. A and Rossini A. A. (1976) "Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus." *Science*, 193(4251): 415-417.

21. Mabley, J. G, Pacher, P, Murthy, K. G. K, Williams, W, Southan, G. J, Salzman, A. L and Szabo, C. (2008) "The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic

mouse models of type I diabetes." *Journal of Endocrinology*, 198(3):581-589.

22. Mabley, J. G, Southan, G. J, Salzman, A. L, Szabo, C. (2004) "The combined inducible nitric oxide synthase inhibitor and free radical scavenger guanidinoethyldisulfide prevents multiple low-dose streptozotocin-induced diabetes in vivo and interleukin-1beta-induced suppression of islet insulin secretion in vitro." *Pancreas*, 28(2): E39-44.

23. Maksimovic-Ivanic, D, Trajkovic, V, Miljkovic D. J, Mostarica Stojkovic, M and Stosic-Grujicic S. (2002) "Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil*.*" *Clinical and Experimental Immunology*, 129(2): 214-223.

24. Nakamura, M, Nagafuchi, S, Yamaguchi, K and Takaki, R. (1984). "The role of thymic immunity and insulitis in the development of streptozocin-induced diabetes in mice." *Diabetes*, 33(9), 894-900.

25. O´Brien, B. A, Harmon, B. V, Cameron, D. P and Allan, D. (1996) "Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model." *The Journal of Pathology*, 178(2):176-181.

26. Ono, J, Takaki, R and Fukuma, M. (1977) "Preparation of single cells from pancreatic islets of adult rats by the use of dispase" *Endocrinologia Japonica*, 24(3):265-270.

27. Padgett, L. E, Broniowska, K. A, Hansen, P. A, Corbett, J. A and Tse, H. M. (2013). "The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis." *Annals of the New York Academy of Sciences*, 1281, 16-35.

28. Paik, S. G, Fleischer, N and Shin S. I. (1980). "Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoinmune processes." *Proceedings of the National Academy of Sciences*, 77(10), 6129-6133.

29. Pastorale, C, Arata, M, Caminos, A, Bruno, L, Basabe, J. C, and Chemes, H. (2002) "Effect of modified diabetic splenocytes on mice injected with multiple low-dose streptozotocin." *Experimental Biology and Medicine*, 227(4): 282-289.

30. Per-Ola, C, Flodstrom, M and Sandler S. (2000) "Islet blood flow in multiple low dose streptozotocin treated wild-type and inducible nitric oxide synthase-deficient mice." *Endocrinology*, 141(8): 2752-2757.

31. Phillips, H. J. (1973) "Dye exclusion test for cell viability", in Kruse G, Patterson C (ed): Tissue: methods and applications. New York, Academic Press, pp 406-408.

32. Pighin, D, Karabatas, L, Pastorale, C, Dascal, E, Carbone, C, Chicco, A, Lombardo, Y. B and Basabe JC. (2005) "Role of lipids in the early developmental stages of experimental immune diabetes induced by multiple low-dose streptozotocin." *Journal of Applied Physiology*, 98(3): 1064-1069.

33. Rydgren, T and Sandler, S. (2002) "Efficacy of 1400 W, a novel inhibitor of inducible nitric oxide synthase, in preventing interleukin-1β-induced suppression of pancreatic islet function in vitro and multiple low-dose streptozotocin-induced diabetes in vivo." *European Journal of Endocrinology*, 147(4): 543-551.

34. Stosic-Grujicic, S. D, Maksimovic, D, Badovinac, V, Samardzić, T, Trajković, V, Lukić, M and Mostarica Stojković, M. (2001) "Antidiabetic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production". *Journal of Autoimmunity*, 16(1):47-58.

35. Wang, Z and Gleichmann, H. (1998) "GLUT2 in pancreatic islets. Crucial target molecule in diabetes induced with

multiple low doses of streptozotocin in mice." *Diabetes*, 47(1): 50-56.

36. Yang, Z, Chen, M, Fialkow, L. B, Ellett, J. D, Wu, R and Nadler, J. L. (2003) "The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice." *Pancreas*, 26(4): E99-E104.

37. Yaochite, J. N, Caliari-Oliveira, C, Davanso, M. R, Carlos, D, Malmegrim, K. C, Cardoso, C. R, Ramalho, L. N, Palma, P. V, da Silva, J. S, Cunha, F. Q, Covas, D. T and Voltarelli, J. C. (2013). "Dymanic changes of the Th17/Tc17 and regulatory T cell populations interfere in the experimental autoinmune diabetes pathogenesis." *Immunobiology*, 218(3), 338-352.

38. Yasuda, H, Jin, Z, Nakayama, M, Yamada, K, Kishi, M, Okumachi, Y, Arai, T, Moriyama, H, Yokono, K and Nagata, M. (2009). "NO-mediated cytotoxicity contribuyes to multiple low-dose streptozotocin-induced diabetes but not to NOD diabetes." *Diabetes Research and Clinical Practice*, 83(2): 200-207.